<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37106076</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1615-6692</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Herz</Title><ISOAbbreviation>Herz</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-More than chronic fatigue?</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>233</EndPage><MedlinePgn>229-233</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00059-023-05170-w</ELocationID><Abstract><AbstractText>After the first COVID-19 survivors were medically treated in Germany from spring 2020 onwards, various courses of the disease emerged that, in addition to the acute infection, led to prolonged symptoms (long COVID), but also to a&#xa0;symptomatic course beyond 12&#xa0;weeks, which is referred to as "post-COVID syndrome" (PCS). Currently, the incidence of PCS is estimated to be approximately 15% of all symptomatically infected patients, although over- or underestimations may occur due to the soft definition and lack of control groups. The etiology of PCS is currently unknown. The following pathogenetic processes are discussed in particular: an endothelial dysfunction with microcirculatory disturbances and subsequent organ damage, a&#xa0;residual virus or virus particles, and/or an excessive autoimmune process. Due to the large number of organs that may be affected, PCS presents as a&#xa0;very complex clinical picture with up to 200 described symptoms. An evidence-based causal therapy for PCS has not yet been established. The guideline-based inpatient rehabilitation measures adapted to the individual patient resources have proven to be an effective therapy and should therefore be involved in the therapeutic concept at an early stage. Post-COVID syndrome is a&#xa0;multicomplex disease that can have a&#xa0;considerable impact on the quality of life, but also on the professional performance of the affected patients. Thus, it is clearly more than just a&#xa0;chronic fatigue syndrome. In the interest of our patients, treating physicians should take this disease seriously, clarify the differential diagnoses, and provide sensitive therapeutic care.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seifart</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Klinik Sonnenblick Marburg, Am&#xf6;neburgerstr. 1-6, 35043, Marburg, Germany. ulf.seifart@drv-hessen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Post-COVID&#xa0;&#x2013; mehr als chronische M&#xfc;digkeit?</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Herz</MedlineTA><NlmUniqueID>7801231</NlmUniqueID><ISSNLinking>0340-9937</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Nachdem ab Fr&#xfc;hjahr 2020 in Deutschland die ersten COVID-19-&#xdc;berlebenden medizinisch behandelt wurden, zeigten sich verschiedene Krankheitsverl&#xe4;ufe, die neben der Akutinfektion eine verl&#xe4;ngerte Symptomatik (Long-COVID), aber auch einen symptomatischen Verlauf &#xfc;ber 12&#xa0;Wochen hinaus boten, der als Post-COVID-Syndrom (PCS) bezeichnet wird. Aktuell wird die H&#xe4;ufigkeit des PCS auf etwa 15&#x202f;% aller symptomatisch infizierten Patienten gesch&#xe4;tzt, wobei es durch die weiche Definition und fehlende Kontrollgruppen zu &#xdc;ber- bzw. Untersch&#xe4;tzungen kommen kann. Die &#xc4;tiologie des PCS ist bisher nicht bekannt. Derzeit werden insbesondere folgende pathogenetische Prozesse diskutiert: eine endotheliale Dysfunktion mit Mikrozirkulationsst&#xf6;rungen und folgender Organsch&#xe4;digung, ein Verbleib des Virus oder von Viruspartikeln und/oder ein &#xfc;berschie&#xdf;endes Autoimmunph&#xe4;nomen. Aufgrund der Vielzahl von m&#xf6;glicherweise betroffenen Organen stellt sich das PCS als sehr komplexes Krankheitsbild mit bis zu 200 beschriebenen Symptomen dar. Eine evidenzbasierte kausale Therapie des PCS ist bis dato nicht etabliert. Die leitliniengerechte, den individuellen Patientenressourcen angepasste station&#xe4;re Rehabilitationsma&#xdf;nahme hat sich als wirksame Therapie bew&#xe4;hrt und sollte somit fr&#xfc;hzeitig in das therapeutische Konzept involviert werden. Das PCS stellt eine multikomplexe Erkrankung dar, welche die Lebensqualit&#xe4;t, aber auch die berufliche Leistungsf&#xe4;higkeit der betroffenen Patienten erheblich tangieren kann und somit deutlich mehr als nur ein chronisches Fatiguesyndrom ist. Im Sinne der Patienten sollte die behandelnden &#xc4;rzte diese Erkrankung ernst nehmen, differenzialdiagnostisch gut abkl&#xe4;ren und therapeutisch sensibel betreuen.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cause</Keyword><Keyword MajorTopicYN="N">Definition</Keyword><Keyword MajorTopicYN="N">Post COVID-19 syndrome</Keyword><Keyword MajorTopicYN="N">Rehabilitation</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword><Keyword MajorTopicYN="N">Therapy</Keyword></KeywordList><CoiStatement>U.&#xa0;Seifart declares that he has no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>27</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37106076</ArticleId><ArticleId IdType="pmc">PMC10136381</ArticleId><ArticleId IdType="doi">10.1007/s00059-023-05170-w</ArticleId><ArticleId IdType="pii">10.1007/s00059-023-05170-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lenzen-Schulte M. Long COVID: Der lange Schatten von COVID-19. Dtsch Arztebl. 2020;117(49):A-2416 / B-2036.</Citation></Reference><Reference><Citation>Nacul L, Authier FJ, Scheibenbogen C, et al. European network on myalgic encephalomyelitis/chronic fatigue syndrome (EUROMENE): expert consensus on the diagnosis, service provision, and care of people with ME/CFS in Europe. Medicina (Kaunas) 2021 doi: 10.3390/medicina57050510.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57050510</ArticleId><ArticleId IdType="pmc">PMC8161074</ArticleId><ArticleId IdType="pubmed">34069603</ArticleId></ArticleIdList></Reference><Reference><Citation>Koczulla AR, Ankermann T, Behrends U, et al. S1-Leitlinie Post-COVID/Long-COVID. Pneumologie. 2021 doi: 10.1055/a-1551-9734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1551-9734</ArticleId><ArticleId IdType="pubmed">34474488</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Moore Vogel J, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L. Post-COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65&#xa0;years&#x2014;United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep. 2021;713:71.</Citation></Reference><Reference><Citation>Ceban F, et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a&#xa0;systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallek M, Adorjan K, Behrends U, et al. Post-COVID syndrome. Dtsch Arztebl Int. 2022;120:48&#x2013;55. doi: 10.3238/arztebl.m2022.0409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.m2022.0409</ArticleId><ArticleId IdType="pmc">PMC10060997</ArticleId><ArticleId IdType="pubmed">36633452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AW, Shah AS, Johnston JC, et al. Patient-reported outcome measures after COVID-19: a&#xa0;prospective cohort study. Eur Respir J. 2020;56:2003276. doi: 10.1183/13993003.03276-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03276-2020</ArticleId><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan NA, Johnson L. Defining long COVID: Going back to the start. Med. 2021;2:501&#x2013;504. doi: 10.1016/j.medj.2021.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2021.03.003</ArticleId><ArticleId IdType="pmc">PMC7992371</ArticleId><ArticleId IdType="pubmed">33786465</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler CGK, Alton SJ, Nyquist SK, et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016&#x2013;1035. doi: 10.1016/j.cell.2020.04.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.035</ArticleId><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmo A, Pereira-Vaz J, Mota V, et al. Clearance and persistence of SARS-CoV-2 RNA inpatients with COVID-19. J Med Virol. 2020;92:2227&#x2013;2231. doi: 10.1002/jmv.26103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26103</ArticleId><ArticleId IdType="pmc">PMC7301002</ArticleId><ArticleId IdType="pubmed">32484958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandetu TB, Dziuban EJ, Sikuvi K, et al. Persistence of positive RT-PCR results for over70&#xa0;days in two travelers with COVID-19. Disaster Med Public Health Prep. 2020 doi: 10.1017/dmp.2020.450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2020.450</ArticleId><ArticleId IdType="pmc">PMC7884651</ArticleId><ArticleId IdType="pubmed">33208199</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Huang K, Jiang H, et al. Long-term existence of SARS-CoV-2 in COVID-19&#xa0;patients: Host immunity, viral virulence, and transmissibility. Virol Sin. 2020;35:793&#x2013;802. doi: 10.1007/s12250-020-00308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-020-00308-0</ArticleId><ArticleId IdType="pmc">PMC7644793</ArticleId><ArticleId IdType="pubmed">33156486</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuken PA, Stallmach A, Pletz MW, et al. Severe clinical relapse in animmunocompromised host with persistent SARS-CoV-2 infection. Leukemia. 2021;35:920&#x2013;923. doi: 10.1038/s41375-021-01175-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01175-8</ArticleId><ArticleId IdType="pmc">PMC7893131</ArticleId><ArticleId IdType="pubmed">33608636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Maejima M, Shibusawa M, et al. Analysis of a&#xa0;persistent viral shedding patientinfected with SARS-CoV-2 by RT-qPCR, FilmArray respiratory panel v2.1, and antigendetection. J Infect Chemother. 2021;27:406&#x2013;409. doi: 10.1016/j.jiac.2020.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiac.2020.10.026</ArticleId><ArticleId IdType="pmc">PMC7598429</ArticleId><ArticleId IdType="pubmed">33183963</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SK, Lee CW, Park DI, et al. Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clin Gastroenterol Hepatol. 2020 doi: 10.1016/j.cgh.2020.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2020.06.005</ArticleId><ArticleId IdType="pmc">PMC7286243</ArticleId><ArticleId IdType="pubmed">32534042</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JM, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16:e0257016. doi: 10.1371/journal.pone.0257016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257016</ArticleId><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Osiaevi I, et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis. 2022 doi: 10.1007/s10456-022-09850-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-022-09850-9</ArticleId><ArticleId IdType="pmc">PMC9366128</ArticleId><ArticleId IdType="pubmed">35951203</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel MA, et al. Elevated vascular transformation blood biomarkers in long-COVID indicate angiogenesis as a&#xa0;key pathophysiological mechanism. Mol Med. 2022;28:122. doi: 10.1186/s10020-022-00548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-022-00548-8</ArticleId><ArticleId IdType="pmc">PMC9549814</ArticleId><ArticleId IdType="pubmed">36217108</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a&#xa0;systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging. 2020;66:35&#x2013;41. doi: 10.1016/j.clinimag.2020.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinimag.2020.05.013</ArticleId><ArticleId IdType="pmc">PMC7233216</ArticleId><ArticleId IdType="pubmed">32425338</ArticleId></ArticleIdList></Reference><Reference><Citation>Morroy G, Keijmel SP, Delsing CE, Bleijenberg G, et al. Fatigue following acute Q-fever: a systematic literature review. PLoS ONE. 2016;11(5):e0155884. doi: 10.1371/journal.pone.0155884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155884</ArticleId><ArticleId IdType="pmc">PMC4880326</ArticleId><ArticleId IdType="pubmed">27223465</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz BZ, Shiraishi Y, Mears CJ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics. 2009;124(1):189&#x2013;193. doi: 10.1542/peds.2008-1879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2008-1879</ArticleId><ArticleId IdType="pmc">PMC2756827</ArticleId><ArticleId IdType="pubmed">19564299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SH, Kim JL, Kim JR, et al. Association between chronic fatigue syndrome and suicidality among survivors of Middle East respiratory syndrome over a 2-year follow-up period. J Psychiatr Res. 2021;137:1&#x2013;6. doi: 10.1016/j.jpsychires.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2021.02.029</ArticleId><ArticleId IdType="pmc">PMC7888998</ArticleId><ArticleId IdType="pubmed">33631632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>